Sp393
GLP-1S IN THE TREATMENT OF OBESITY AND DIABETES
Date
May 7, 2023
Explore related products in the following collection:
Tracks
Related Products
MACHINE-LEARNING DRIVEN, FULL PHENOTYPE MODEL AND SURROGATE POLYGENIC RISK SCORE MODEL FOR APPETITE PREDICT RESPONSE TO GLP-1 RECEPTOR AGONIST IN PATIENTS WITH OBESITY
Background: Transoral outlet reduction endoscopy (TORe) has been shown to be effective in managing weight regain after Roux-en-Y gastric bypass (RYGB), as has the glucagon-like peptide-1 agonist, liraglutide. However, the effect of adjunctive liraglutide after TORe has yet to be assessed…
IMPACT OF HETEROZYGOUS GENETIC VARIANTS IN THE LEPTIN-MELANOCORTIN PATHWAY ON WEIGHT LOSS OUTCOMES FOLLOWING ENDOSCOPIC TRANSORAL OUTLET REDUCTION AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY
BACKGROUND: Sound evidence support the effectiveness of the transoral outlet reduction (TORe) with full-thickness endoscopic suturing (FTS) or argon plasma coagulation (APC) alone to address post-RYGB weight regain…
REGULATOR OF G-PROTEIN SIGNALING AS AN ENTEROENDOCRINE-SPECIFIC TARGET FOR OBESITY TREATMENT: ALTERED RGS9 IN ENTEROENDOCRINE CELLS IMPAIRS POSTPRANDIAL GLP-1 RESPONSE AND MODIFIES FOOD INTAKE IN MICE
Enteroendocrine cells play a major role in sensing the luminal contents of the gut and communicating with other organs such as the pancreas, liver and brain. The gut-brain connection is essential in the regulation of food intake…